Pure Storage vs Recursion Pharmaceuticals Inc — how do they compare? Pure Storage trades at $154.84 (market cap $50.17B), while Recursion Pharmaceuticals Inc trades at $4.32 (market cap $2.14B). The key difference: Pure Storage is far larger — about 23.4× Recursion Pharmaceuticals Inc's market cap, and Pure Storage is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Pure Storage for 3 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| P | RXRX | |
|---|---|---|
Market Cap | $50.17B | $2.14B |
Volume | 5,733,762 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $152.84 | $6.79 |
52-Week Low | $56.99 | $2.84 |
Typical Hold Time | 3 Days | 23 Days |
Enterprise Value | $49.39B | $1.66B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Pure Storage develops enterprise data storage and data management systems, primarily using all-flash technology. Its platform supports cloud, AI, analytics, and mission-critical application workloads.
Read more on P →Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →